Whalesbook
Tata Elxsi announced its Q4 FY26 results, with operating revenue reaching ₹993.8 crore. The company also reported a sequential improvement in its EBITDA margin, which climbed to 24.6%. This margin expansion was attributed to better operational efficiencies and favorable currency movements.
Performance across business segments showed mixed trends. Revenue in the Transportation segment saw modest growth of 0.2% in constant currency quarter-on-quarter, while Media & Communications grew by 5.6%. However, the Healthcare & Life Sciences division experienced a significant 13.1% decline in constant currency, largely due to delays in deal awards. Management suggested that this quarter may represent the low point for the Healthcare segment.
For the full fiscal year 2026, Tata Elxsi reported total revenue of ₹3,757.4 crore and a Profit Before Tax (PBT) margin of 23.4%. The company's strategy continues to focus on scaling its AI-enabled services and enhancing operational leverage. A notable shift involves a greater emphasis on OEM clients in the Transportation vertical, which now constitute 77% of that segment's revenue.
Looking ahead to fiscal year 2027, management has revised its growth expectations to higher single digits, a moderation from previous double-digit targets. This more cautious outlook stems from global uncertainties and challenges specific to certain industry segments. Key risks for the company include continued delays in securing new deals, particularly impacting the Healthcare and Life Sciences unit. Volatility in the automotive market due to geopolitical factors could also affect demand. Furthermore, the Media and Telecom industry faces ongoing pressure for cost reduction, which may limit growth opportunities. Longer-tenure contracts can also incur higher initial costs, potentially impacting margins in their first year.
In the broader industry context, L&T Technology Services (LTTS) reported FY26 revenue of approximately ₹10,996 crore with a 14.5% EBIT margin. KPIT Technologies, another player focused on automotive software, posted Q1 FY26 revenue around ₹1,480 crore and an EBITDA margin of 21%.
Investors will be monitoring the recovery and growth in the Healthcare and Life Sciences vertical during the first quarter of FY27. The success and scaling of new large deals, especially in the Automotive sector, will be critical. Progress in developing emerging verticals such as Aerospace & Defense will also be watched. Additionally, management's progress towards achieving target PBT margins of 27-28% for FY27 will be a key metric.